Logan Richards | Unicycive Therapeutics: A Catalyst Play With Real Fundamental Upside
Biography: “I hold a Ph.D. in the biological sciences, with advanced research experience focused on molecular biology and DNA replication. My investing approach is strictly bottom-up, fundamental, and risk-managed. I utilize risk-adjusted net present value (rNPV) modeling, rigorous pipeline scrutiny, and competitive landscape mapping to identify mispriced opportunities, particularly those trading at a dislocation relative to their upcoming clinical or regulatory milestones.”
Strong Buy | “Unicycive Therapeutics, Inc. (UNCY) is valued at $8/share, with $2/share in cash and the pipeline—primarily OLC—valued at $6/share. OLC targets hyperphosphatemia by reducing pill burden, aiming for improved patient adherence, with a PDUFA date set for June 29, 2026.
Key risks include payer acceptance of premium pricing, patent term uncertainty, and lack of outcomes data supporting improved adherence. I see a 60% upside to $13.90/share based solely on OLC, but I recommend trading around the PDUFA catalyst due to commercial and patent risks.